Economic evaluation of diabetes prevention: informing global health implementation decisions

Andrew Mirelman

doi:10.1016/S2213-8587(16)30289-3

Economic evaluation of diabetes prevention: informing global health implementation decisions

Andrew Mirelman

Centre for Health Economics

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Decisions to improve health in the face of the rising epidemic of non-communicable diseases (NCD) in low-income and middle-income countries (LMICs) hinge on how to provide the best care with existing technologies. In many cases, however, the implementation technology needs careful evaluation, including how well it responds to the needs of citizens and health policy makers. Application of economic analysis to these questions can show how such implementation decisions affect health resources and balance benefits and harms.

Original language	English
Pages (from-to)	879-880
Number of pages	2
Journal	Lancet Diabetes Endocrinol
Volume	4
Issue number	11
DOIs	https://doi.org/10.1016/S2213-8587(16)30289-3
Publication status	Published - 1 Nov 2016

Access to Document

10.1016/S2213-8587(16)30289-3

http://www.thelancet.com/pdfs/journals/landia/PIIS2213-8587(16)30289-3.pdf

Cite this

@article{e9d4af2a45684b6bb7b9423040b429da,

title = "Economic evaluation of diabetes prevention: informing global health implementation decisions",

abstract = "Decisions to improve health in the face of the rising epidemic of non-communicable diseases (NCD) in low-income and middle-income countries (LMICs) hinge on how to provide the best care with existing technologies. In many cases, however, the implementation technology needs careful evaluation, including how well it responds to the needs of citizens and health policy makers. Application of economic analysis to these questions can show how such implementation decisions affect health resources and balance benefits and harms.",

author = "Andrew Mirelman",

year = "2016",

month = nov,

day = "1",

doi = "10.1016/S2213-8587(16)30289-3",

language = "English",

volume = "4",

pages = "879--880",

journal = "Lancet Diabetes Endocrinol",

issn = "2213-8595",

publisher = "Elsevier",

number = "11",

}

TY - JOUR

T1 - Economic evaluation of diabetes prevention

T2 - informing global health implementation decisions

AU - Mirelman, Andrew

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Decisions to improve health in the face of the rising epidemic of non-communicable diseases (NCD) in low-income and middle-income countries (LMICs) hinge on how to provide the best care with existing technologies. In many cases, however, the implementation technology needs careful evaluation, including how well it responds to the needs of citizens and health policy makers. Application of economic analysis to these questions can show how such implementation decisions affect health resources and balance benefits and harms.

AB - Decisions to improve health in the face of the rising epidemic of non-communicable diseases (NCD) in low-income and middle-income countries (LMICs) hinge on how to provide the best care with existing technologies. In many cases, however, the implementation technology needs careful evaluation, including how well it responds to the needs of citizens and health policy makers. Application of economic analysis to these questions can show how such implementation decisions affect health resources and balance benefits and harms.

U2 - 10.1016/S2213-8587(16)30289-3

DO - 10.1016/S2213-8587(16)30289-3

M3 - Comment/debate

C2 - 27717765

SN - 2213-8595

VL - 4

SP - 879

EP - 880

JO - Lancet Diabetes Endocrinol

JF - Lancet Diabetes Endocrinol

IS - 11

ER -